Comparative Pharmacology
Head-to-head clinical analysis: AUREOMYCIN versus BISMUTH SUBSALICYLATE METRONIDAZOLE AND TETRACYCLINE HYDROCHLORIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AUREOMYCIN versus BISMUTH SUBSALICYLATE METRONIDAZOLE AND TETRACYCLINE HYDROCHLORIDE.
AUREOMYCIN vs BISMUTH SUBSALICYLATE, METRONIDAZOLE AND TETRACYCLINE HYDROCHLORIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Binds to the 30S ribosomal subunit, inhibiting protein synthesis by blocking aminoacyl-tRNA binding.
Bismuth subsalicylate exerts antimicrobial and anti-inflammatory effects via binding to gastrointestinal mucosa and inhibiting prostaglandin synthesis; metronidazole inhibits DNA synthesis by forming nitro radical anions; tetracycline inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit.
250-500 mg orally every 6 hours; or 10-20 mg/kg/day intravenously divided every 12 hours
Each dose consists of 2 capsules (each containing bismuth subsalicylate 262.4 mg, metronidazole 250 mg, and tetracycline hydrochloride 375 mg) taken orally 3 times daily (after meals) for 10 days.
None Documented
None Documented
Terminal elimination half-life: 8–12 hours (prolonged in renal impairment; may extend to 20–30 hours in anuria)
Bismuth subsalicylate: Bismuth component ~5 days (accumulation risk), salicylate 2–3 hours; Metronidazole: 8 hours (increased in hepatic impairment); Tetracycline HCl: 6–12 hours (prolonged in renal impairment).
Renal (70% unchanged), biliary/fecal (30% as metabolites and unchanged drug)
Bismuth subsalicylate: Renal excretion of salicylate and bismuth (bismuth largely fecal as insoluble sulfide); Metronidazole: Renal 60–80% (unchanged and metabolites), fecal 6–15%; Tetracycline HCl: Renal 60% unchanged, fecal 40% (biliary and direct excretion).
Category C
Category D/X
Tetracycline Antibiotic
Tetracycline Antibiotic